Market Review on Glutamate Receptor Ionotropic NMDA 2B NMDA Receptor Subunit Epsilon 2 -Pipeline Review, H1 2016

Glutamate Receptor Ionotropic NMDA 2B NMDA Receptor Subunit Epsilon 2 or GRIN2B-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted pipeline therapeutics.

The report provides comprehensive information on the Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics development and features dormant and discontinued projects.

Complete report available @ Glutamate Receptor Ionotropic NMDA 2B NMDA Receptor Subunit Epsilon 2 or GRIN2B-Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B)
- The report reviews Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics

Reasons to buy

- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

BioCrea GmbH Bristol-Myers Squibb Company Cerecor Inc. Johnson & Johnson Luc Therapeutics, Inc. NeurOp, Inc Novartis AG UCB S.A.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###